Literature DB >> 12684925

Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.

Melissa D Murphy1, Mary O'Hearn, Sunwen Chou.   

Abstract

We describe a 49-year-old man with human immunodeficiency virus infection and stable chronic renal insufficiency who developed acute oliguric renal failure and severe lactic acidosis and who died several weeks after tenofovir was added to an antiretroviral regimen that included didanosine. Although the role of tenofovir in precipitating acute renal failure is unclear, progressive accumulation of the drug and pharmacologic interaction that caused increased levels of didanosine were the likely antecedents of increased mitochondrial toxicity that led to lactic acidosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684925     DOI: 10.1086/368313

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Disease management--constructing optimal NRTI-based combinations: past, present, and future.

Authors:  Douglas T Dieterich
Journal:  MedGenMed       Date:  2006-01-19

3.  Rapid Onset of Fatal Lactic Acidosis Complicating Tenofovir Therapy in a Diabetic Patient with Cirrhosis: A Cautionary Tale.

Authors:  Ramesh Kumar; Shivani Agrawal
Journal:  J Clin Exp Hepatol       Date:  2016-08-28

4.  Drug-Induced Liver Injury in HIV Patients.

Authors:  Guy W Neff; Dushyantha Jayaweera; Kenneth E Sherman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-06

Review 5.  HIV and the kidney: a status report after 20 years.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

6.  Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

Authors:  Marta Boffito; David Back; Meredith Stainsby-Tron; Andrew Hill; Giovanni Di Perri; Graeme Moyle; Mark Nelson; Jaqui Tomkins; Brian Gazzard; Anton Pozniak
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

Review 7.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 8.  The nephrotoxic effects of HAART.

Authors:  Hassane Izzedine; Marianne Harris; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

9.  Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Authors:  Alain Pruvost; Eugènia Negredo; Frédéric Théodoro; Jordi Puig; Mikaël Levi; Rafaela Ayen; Jacques Grassi; Bonaventura Clotet
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

10.  Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future.

Authors:  Douglas T Dieterich
Journal:  J Int AIDS Soc       Date:  2006-01-19       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.